Market Herald logo


Be the first with the news that moves the market
  • Medical device company EMVision is raising $4.5 million to fund developing its portable brain scanner
  • The company says it is looking to continue advancing its medical tech devices and clinical validation
  • Shareholders will be able to buy into the company at 74 cents per share, marking a 13 per cent discount on its last closing price
  • After falling and rising on the Australian market today, at market close the company’s share price has fallen flat
  • Shares in the company are currently trading for 85 cents each

To help fund its product development EMVision is raising $4.5 million from shareholders.

The company specialises in developing and commercialising medical imaging technology. The funds raised will be used specifically to advance its portable brain-scanning device and to continue clinical validation.

“The funds raised will provide a stronger balance sheet to enable EMVision to execute on our product development and clinical validation strategy,” company Chairman John Keep said.

In its release to the Australian market today, the company outlined is has received funding commitments from both institutional and sophisticated investors.

“We are delighted with the support of existing shareholders and the opportunity to welcome a number of high-quality institutions to our register,” John added.

Shareholders will have the opportunity to buy into the company at 74 cents per share, marking a 13 per cent discount from yesterday’s closing price.

During early trade shares in the company fell four per cent but spiked over 11 per cent after 12:00pm AEDT. However, EMVision’s share price has settled flat again as market close approaches.

Shares in the company are currently trading for 85 cents each.

EMV by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.